Skip to Content

'
Martin J. Korbling

Present Title & Affiliation

Primary Appointment

Professor of Medicine & Internist, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 423
Houston, TX 77030
Room Number: FC5.3056
Email: mkorblin@mdanderson.org

Education & Training

Degree-Granting Education

1972 Heidelberg University Medical School, Heidelberg, Germany, Medical Doctor, MD

Postgraduate Training

1979-1980 Fellowship, Johns Hopkins University Medical School, Baltimore, MD
1975-1978 Fellowship, Ulm University, Ulm, Germany
1974 Internship, Munich University, Garmisch-Partenkirchen, Germany
1973 Internship (Medizinalassistent), Heidelberg University Hospital, Heidelberg, Germany

Board Certifications

1990 Board Certification-Internal Medicine

Honors and Awards

2012 Honorary Membership of the German Society of Hematology, German Society for Hematology and Oncology
2007-2011 Devices and methods for extracorporeal ablation of circulating cells, United States Patent 8,057,418
2001 National Leadership Award, The National Congressional Committee, Honorary Co-Chairman, Physicians Advisory Board
1988 Proffered Paper Presentation, Main Symposium of the XXII Congress of the International Society of Hematology, Milan, Italy
1987 Best Presentation Award, Annual Meeting of the German Society of Internal Medicine
1986 Karl-Heinrich-Bauer Gedächtnispreis, on the occasion of the 600th anniversary of the Heidelberg University, ($ 15,000.-)
1977 Research Award, Ulm, West Germany

Selected Publications

Peer-Reviewed Original Research Articles
1. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T-cell Replete Graft Compared with T-cell Depleted Haploidentical Hematopoietic Stem-Cell Transplantation. Biol Blood Marrow Transplant. e-Pub 7/10/2012. PMID: 22796535.
2. Khouri IF, Saliba RM, Erwin WD, Samuels BI, Korbling M, Medeiros LJ, Valverde R, Alousi AM, Anderlini P, Bashir Q, Ciurea S, Gulbis AM, de Lima M, Hosing C, Kebriaei P, Popat UR, Fowler N, Neelapu SS, Samaniego F, Champlin RE, Macapinlac HA. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood. e-Pub 5/14/2012. PMID: 22586182.
3. Ciurea SO, Thall PF, Wang X, Wang SA, Hu Y, Cano P, Aung F, Rondon G, Molldrem JJ, Korbling M, Shpall EJ, de Lima M, Champlin RE, Fernandez-Vina M. Donor-specific anti-HLA antibodies and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 118(22):5957-64, 11/24/2011. e-Pub 10/3/2011. PMID: 21967975.
4. Körbling M, Freireich EJ. 25 years of peripheral blood stem cell transplantation. Blood 117(24):6411-6, 6/16/2011. e-Pub 4/1/2011. PMID: 21460243.
5. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, Qureshi S, Worth LL, McMannis J, Kebriaei P, Jones RB, Korbling M, Qazilbash M, Shpall EJ, Giralt S, de Lima M, Champlin RE, Gajewski J. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant 45(3):429-36, 3/2010. e-Pub 8/2009. PMID: 19668237.
6. Hosing C, Munsell MF, Reuben JM, Popat U, Lee BN, Gao H, Körbling M, Shpall EJ, Kebriaei P, Alousi A, De Lima M, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I. A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas. J Blood Med 1:49-55, 2010. e-Pub 4/14/2010. PMCID: PMC3262333.
7. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, Wang X, Thall PF, Champlin RE, Fernandez-Vina M. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 88(8):1019-24, 10/2009. PMID: 19855248.
8. Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 6/2009. PMID: 19384931.
9. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6). e-Pub 4/2009. PMID: 19450756.
10. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C, Kebraei P, Harrell R, Rondon G, Giralt SA, Anderlini P, Popat U, Pro B, Samuels B, Hagemeister F, Medeiros LJ, Champlin RE, Khouri IF. Mature results of the MD Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113(18). e-Pub 1/2009. PMID: 19168784.
11. Alousi AM, Saliba RM, Okoroji GJ, Macapinlac HA, Hosing C, Korbling M, Samuels BI, Popat U, Kebriaei P, Anderlini P, Qazilbash MH, de Lima M, Giralt SA, Champlin RE, Khouri IF. Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation. Br J Haematol 142(5). e-Pub 6/2008. PMID: 18564354.
12. Khouri IF, McLaughlin P, Saliba RM, Hosing C, Korbling M, Lee MS, Medeiros LJ, Fayad L, Samaniego F, Alousi A, Anderlini P, Couriel D, de Lima M, Giralt S, Neelapu SS, Ueno NT, Samuels BI, Hagemeister F, Kwak LW, Champlin RE. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 111(12):5530-6, 6/2008. PMID: 18411419.
13. Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, Roberson S, Giralt S, Pierre B, Russell JA, Shpall EJ, Jones RB, Champlin RE. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 14(6):672-84, 6/2008. PMID: 18489993.
14. Martin Korbling, Marcos J de Lima, Elizabeth Thomas, Abha Khanna, Amer M Najjar, Jun Gu, Juri G Gelovani, and Russell Broaddus. Fusion of circulating blood cells with solid-organ tissue cells in clinical stem cell transplants: a potential therapeutic model. Regen Med 3:157, 2008.
15. Khouri IF, Saliba RM, Admirand J, O'Brien S, Lee MS, Korbling M, Samuels BI, Giralt S, Lima de M, Keating MJ, Champlin RE, Bueso-Ramos C. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol 137(4):355-63, 5/2007.
16. Oran B, Donato M, Aleman A, Hosing C, Korbling M, Detry MA, Wei C, Anderlini P, Popat U, Shpall E, Giralt S, Champlin RE. Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment. Biol Blood Marrow Transplant 13(4):469-77, 4/2007.
17. Korbling M, Reuben JM, Gao H, Lee BN, Harris DM, Cogdell D, Giralt SA, Khouri IF, Saliba RM, Champlin RE, Zhang W, Estrov Z. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion 46:1795-802, 10/2006. PMID: 17002637.
18. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. Bone Marrow Transplant 38:421-6, 9/2006. PMID: 16892072.
19. Hosing C, Saliba RM, Korbling M, Acholonu S, McMannis J, Anderlini P, Giralt S, De Lima M, Okoroji GJ, Couriel DR, Champlin R, Khouri IF, Donato ML. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 47:1290-4, 7/2006. PMID: 16923559.
20. Hosing C, Qazilbash MH, Kebriaei P, Giralt S, Davis MS, Popat U, Anderlini P, Shpall EJ, McMannis J, Korbling M, Champlin RE. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol 133:533-7, 6/2006. PMID: 16681642.
21. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, Couriel D, De Lima M, Donato ML, Fayad L, Giralt S, Jones R, Korbling M, Maadani F, Manning JT, Pro B, Shpall E, Younes A, McLaughlin P, Champlin RE. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 23(10):2240-7, 4/2005. PMID: 15800314.
22. Obeyesekere MN, Berry RW, Spicer PP, Korbling M. A mathematical model of haemopoiesis as exemplified by CD34 cell mobilization into the peripheral blood. Cell Prolif 37(4):279-94, 8/2004. PMID: 15245564.
23. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, Shpall EJ, Shahjahan M, Pierre B, Giralt S, Korbling M, Russell JA, Champlin RE, Andersson BS. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104(3):857-64, 8/2004. PMID: 15073038.
24. Hennessy B, Korbling M, Estrov Z. Circulating stem cells and tissue repair. Panminerva Med 46(1):1-11, 3/2004. PMID: 15238877.
25. Pentz RD, Chan KW, Neumann JL, Champlin RE, Korbling M. Designing an ethical policy for bone marrow donation by minors and others lacking capacity. Camb Q Healthc Ethics 13(2):149-55, 2004. PMID: 15124402.
26. Monaco G, Konopleva M, Munsell M, Leysath C, Wang RY, Jackson CE, Korbling M, Estey E, Belmont J, Andreeff M. Engraftment of acute myeloid leukemia in NOD/SCID mice is independent of CXCR4 and predicts poor patient survival. Stem Cells 22(2):188-201, 2004. PMID: 14990858.
27. Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 32(1):28-35, 2004. PMID: 14725898.
28. Yeh ET, Zhang S, Wu HD, Korbling M, Willerson JT, Estrov Z. Transdifferentiation of human peripheral blood CD34+-enriched cell population into cardiomyocytes, endothelial cells, and smooth muscle cells in vivo. Circulation 108(17):2070-3, 10/2003. PMID: 14568894.
29. Korbling M, Estrov Z, Champlin R. Adult stem cells and tissue repair. Bone Marrow Transplant 32 Suppl 1:S23-4, 8/2003. PMID: 12931235.
30. Duzkale H, Pagliaro LC, Rosenblum MG, Varan A, Liu B, Reuben J, Wierda WG, Korbling M, McMannis JD, Glassman AB, Scheinberg DA, Freireich EJ. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel. Biol Blood Marrow Transplant 9(6):364-72, 6/2003. PMID: 12813444.
31. Apisarnthanarax N, Donato M, Korbling M, Couriel D, Gajewski J, Giralt S, Khouri I, Hosing C, Champlin R, Duvic M, Anderlini P. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant 31(6):459-65, 3/2003. PMID: 12665841.
32. Wang, RY, Weidner D, McQueen T, McMannis J, Korbling M, Champlin R, Andreeff M. Quantitative determination of Bcl-2 expression in AML cell lines and in normal and leukemic progenitor cell compartments by laser scanning cytometry: Comparison with flow cytometry and Western blot. Acute Leukemias IX:239-251, 1/2003.
33. Korbling, M, Estrov Z. Adult stem cells for tissue repair - a new therapeutic concept? N Engl J Med 349:570-582, 2003.
34. De Lima M, St John LS, Wieder ED, Lee MS, McMannis J, Karandish S, Giralt S, Beran M, Couriel D, Korbling M, Bibawi S, Champlin R, Komanduri KV. Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units. Br J Haematol 119(3):773-6, 12/2002. PMID: 12437658.
35. Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 30(10):661-3, 11/2002. PMID: 12420204.
36. Anderlini P, Chan FA, Champlin RE, Korbling M, Strom SS. Long-term follow-up of normal peripheral blood progenitor cell donors treated with filgrastim: no evidence of increased risk of leukemia development. Bone Marrow Transplant 30(10):661-3, 11/2002. PMID: 12420204.
37. Brouard, M, Barrandon Y, Stevens AM, McDonnell WM, Nelson JL, Taussig D, Pearce DJ, Bonnet DA, Kaygusuz A, Akarsu AN, Tuncer AM, Korbling M, Estrov Z. N Engl J Med 347:218-220, 2002.
38. Estrov, Z, Huh YO, Harris D, Van Q, Mirza NQ, Talpaz M, Korbling M. A simple method for ex vivo expansion of hematopoietic progenitors. Journal of Clinical Apheresis 17(1):7-16, 2002.
39. Estrov Z, Huh YO, Ginsberg CF, Harris D, Van Q, Mirza NQ, Talpaz M, Korbling M. Ex vivo expansion of apheresis-derived peripheral blood hematopoietic progenitors. J Clin Apher 17(1):7-16, 2002. PMID: 11948700.
40. Korbling, M, Katz RL, Khanna A, Ruifrok AC, Rondon G, Albitar M, Champlin RE, Estrov Z. Generation of skin, gut, and liver epithelial cells by circulating stem cells in patients undergoing allogeneic peripheral blood stem cell transplantation. N Engl J Med 346(10):738-746, 2002.
41. Shimoni, A, Korbling M. Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance? . Crit Rev Oncol Hematol 41(2):241-250, 2002.
42. Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C, Benyunes M, Miller LL, LaTemple D, Jones D, Ashby M, Hellmann S, Durett A, Lauppe J, Geisler D, Khouri IF, Giralt SA, Andersson B, Ueno NT, Champlin R. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant 8(10):550-6, 2002. PMID: 12434950.

Abstracts
1. Zaher I Chakhachiro, MD1*, Rima M Saliba, Ph.D.2*, Grace-Julia Okoroji2*, Martin Korbling, MD2*, Amin M Alousi, MD2*, Chitra M Hosing, MD2, Marcos De Lima, MD3, Paolo Anderlini, MD4, Uday Popat, M.D.2, Barry I Samuels, MD5*, L. Jeffrey Medeiros, MD6, Carlos E. Bueso-Ramos, MD, PhD7, Richard Champlin, MD4 and Issa F Khouri, MD4. 12-Year Experience with High-Dose Rituximab-Containing Autologous Stem Cell Transplantation for SOX11-Positive Mantle Cell Lymphoma Patients in First Remission: Emerging Lymphoma-Free Survival Plateau After 3 Years. ASH Annual Meeting 2011 Abstract, 1/2012.
2. Amer Beitinjaneh, MD, MPH1, Rima M. Saliba, PhD2*, Grace-Julia Okoroji3*, Martin Korbling, MD2*, Amin M Alousi, MD2*, Uday Popat, MD4, Paolo Anderlini, MD5, Qaiser Bashir, MD6*, Borje S Andersson, MD, PhD5*, Partow Kebriaei, MD7, Chitra M Hosing, MD6, Muzaffar Qazilbash, MD1, Michelle A. Fanale, MD8, Barbara Pro, MD9*, Richard Champlin, MD6 and Issa Khouri, MD10. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphoma: The M.D. Anderson Cancer Center Experience. ASH Annual Meeting 2011 Abstract, 1/2012.
3. Lisa Zipp, MS1*, Rima M Saliba, Ph.D.1*, Rosamar Valverde2*, Grace-Julia Okoroji1*, Martin Korbling, MD1*, Barry I Samuels, MD3*, Lynne V. Abruzzo, MD, PhD4, Amin M Alousi, MD1*, Borje S Andersson, MD, PhD5*, Chitra M Hosing, MD1, Bill Erwin, MS6*, Paolo Anderlini, MD5, Uday R Popat, MD1, Partow Kebriaei1, Homer A Macapinlac, MD7*, Richard Champlin, MD5 and Issa F. Khouri, MD8. Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies. ASH Annual Meeting 2011 Abstract, 1/2012.
4. Issa F Khouri, MD1, Rima M Saliba, Ph.D.2*, Rosamar Valverde3*, Barry I Samuels, MD4*, Martin Korbling, MD2*, Amin M Alousi, MD2*, Paolo Anderlini, MD1, Qaiser Bashir, MD1*, Marcos De Lima, MD5, Chitra Hosing, MD6, Partow Kebriaei, MD7, Yago Nieto, MD, PhD2, Uday R Popat, MD2, Muzaffar Qazilbash, MD1, Sattva Neelapu, MD8, Nathan H. Fowler, MD6, Felipe Samaniego, MD8, Luhua Wang, MD9, Richard Champlin, MD1 and Homer A Macapinlac, MD10*. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. ASH Annual Meeting 2011 Abstract, 1/2012.
5. Issa F Khouri, MD1, Rima M Saliba, PhD1*, Martin Korbling, MD2*, Amin M Alousi, MD2*, Uday R Popat, MD2, Paolo Anderlini, MD3, Stefan O Ciurea, MD2, Partow Kebriaei, MD4, Muzaffar H. Qazilbash, MD5*, Richard Champlin, MD2 and Roland L Bassett Jr. Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd. ASH Annual Meeting 2011 Abstract, 1/2012.

Book Chapters
1. M. Korbling. Stem Cell Grafts. In: Hematopoietic Stem Cell Transplantation: A Clinician's Handbook. Ed(s) JR Wingard, D Castineau, H Leather, EL Snyder, ZM Szczepiorkowski, 2009.

Grant & Contract Support

Title: Extracorporeal thermo-ablation of circulating cancer cells/stem cells using targeted nanoshells
Funding Source: NIH/SBIR
Role: Principal Co-Investigator
Duration: 2008 - 2010

Last updated: 3/5/2013